Because AXL is emerging as a promising drug target to limit certain metastatic cancers including TNBC [5, 8, 10], we sought to identify drugs that could be repurposed based on their induction of a gene signature similar to that seen with AXL depletion. This evidence concerns the gene AXL and metastatic malignant neoplasm.